OR WAIT null SECS
Under the terms of the partnership, ICQ Consultants will provide consulting and engineering services for the installation, maintenance, qualification, and support of Yokogawa's bioreactor systems and related products in the US.
Yokogawa Electric Corporation, a Japanese electrical engineering and software company, and Integrated Commissioning and Qualification Consultants (ICQ Consultants), a US-based biotechnology company, announced on Feb. 24, 2021 that they have entered into a partnership through which ICQ Consultants will provide consulting and engineering services for the installation, maintenance, qualification, and support of Yokogawa's bioreactor systems and related products in the US.
Through the collaboration, Yokogawa will gain access to ICQ Consultants’ engineering and laboratory expertise in the biopharmaceutical market to launch its bioprocess technologies in the US, Yokogawa said in a company press release. Yokogawa’s first portfolio product from the partnership is the Advanced Control Bioreactor System BR1000. Released on Jan. 8, 2021, the new system works to automate lab-scale mammalian cell culture with real-time monitoring and advanced process control.
"We are very excited to join Yokogawa in this strategic partnership agreement to help facilitate the support of their bioreactor systems and related products throughout the United States,” said Michael Bogan, president of ICQ Consultants, in the press release. “As ICQ Consultants continues to expand operations across the country, we are poised to further develop lasting relationships, which has been a key factor in our ongoing success. I look forward to working with Yokogawa on this unique and collaborative opportunity.”
“Alliances with industry experts like ICQ Consultants are vital to gain expertise and penetration in the high growth biopharmaceutical market,” added Hiroshi Nakao, a Yokogawa vice president and head of the company's Life Innovation Business Headquarters, in the press release. “ICQ Consultants’ engineering and technical knowledge in drug manufacturing will support our innovative new bioreactor and bioprocess technologies and help position Yokogawa for rapid sales and market leadership in the emerging bio-industrial autonomy sector."